The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMA | -69.21% | N/A | N/A | -65% |
| S&P | +14.78% | +87.14% | +13.33% | +8% |
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
No news articles found for ImageneBio.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 100.0% |
| Gross Margin | 53.72% | 0.0% |
| Market Cap | $91.13M | 9.2% |
| Market Cap / Employee | $9.11M | 0.0% |
| Employees | 10 | -76.7% |
| Net Income | -$24,779.00K | -142.1% |
| EBITDA | -$26,296.00K | -128.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $103.16M | 128.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.79M | 96.7% |
| Short Term Debt | $2.16M | -44.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.23% | 3.5% |
| Return On Invested Capital | -36.06% | 11.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26,642.00K | -198.1% |
| Operating Free Cash Flow | -$26,642.00K | -198.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.63 | 0.52 | 0.56 | 0.28 | -54.53% |
| Price to Sales | 10.28 | 17.81 | 43.18 | 126.69 | - |
| Price to Tangible Book Value | 7.08 | 5.89 | 6.56 | 0.28 | -96.21% |
| Enterprise Value to EBITDA | 3.12 | 4.93 | 3.03 | 2.36 | -41.10% |
| Return on Equity | -33.3% | -30.5% | -23.8% | -33.0% | -10.88% |
| Total Debt | $7.52M | $6.61M | $5.68M | $10.96M | 30.51% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
